Billwin Industries Limited (BOM:543209)

Oncternal Therapeutics Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	6.79	7.81	7.42	2.19	0.56
Depreciation & Amortization	0.12	0.05	0.06	0.08	0.11
Other Operating Activities	3.13	6.22	5.72	3.93	3.49
Change in Accounts Receivable	-27.42	-6.9	-14.68	12.5	9.87
Change in Inventory	-0.79	-4.01	-1.11	-10.58	-26.12
Change in Accounts Payable	-5.68	5.76	1.58	-1.62	-1.22
Change in Other Net Operating Assets	-1.56	-2.64	-0.11	6.05	-2.67
Operating Cash Flow	-25.41	6.28	-1.11	12.54	-16
Capital Expenditures	-0.99	-	-	-	-
Investment in Securities	-0.85	1.1	-0.21	-0.17	-
Investing Cash Flow	-2.13	0.88	-0.3	-0.56	-2.49
Long-Term Debt Issued	-	-	5.65	-	3.77
Short-Term Debt Repaid	-26.34	-	-	-	-
Long-Term Debt Repaid	-14.85	-3.43	-	-8.59	-
Total Debt Repaid	-41.19	-3.43	-	-8.59	-
Net Debt Issued (Repaid)	-41.19	-3.43	5.65	-8.59	3.77
Issuance of Common Stock	69.67	-	-	-	17.98
Other Financing Activities	-1.21	-3.59	-3.94	-3.38	-3.29
Financing Cash Flow	27.27	-7.02	1.7	-11.97	18.46
Miscellaneous Cash Flow Adjustments	0	-0	-0	0	-0
Net Cash Flow	-0.27	0.14	0.29	0	-0.03
Free Cash Flow	-26.4	6.28	-1.11	12.54	-16
Free Cash Flow Margin	-37.42%	12.67%	-2.31%	28.57%	-56.17%
Free Cash Flow Per Share	-6.88	2.95	-0.52	5.88	-8.14
Cash Interest Paid	1.21	3.35	3.76	3.12	3.09
Cash Income Tax Paid	1	-	0.85	0.24	-
Levered Free Cash Flow	-27.94	-0.56	-3.43	1.81	-19.38
Unlevered Free Cash Flow	-27.19	1.54	-1.08	3.76	-17.45
Change in Net Working Capital	33.54	7.28	9.9	0.31	20.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.